YHC 1108
Alternative Names: YHC-1108Latest Information Update: 18 Dec 2025
At a glance
- Originator Yuhan
- Developer Gilead Sciences; Yuhan
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 27 Nov 2025 Discontinued - Preclinical for Non-alcoholic steatohepatitis in South Korea, USA (unspecified route) (Yuhan pipeline, November 2025)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in South Korea
- 28 Jun 2025 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA